Cytokinetics - CYTK Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $81.60
Forecasted Upside: 37.07%
Number of Analysts: 15
Breakdown:
0 Sell Ratings
2 Hold Ratings
13 Buy Ratings
0 Strong Buy Ratings

^$59.53 As of 05/17/2024 01:00 AM ET

▼ -0.39 (-0.65%)

1 month | 3 months | 12 months

Get New Cytokinetics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CYTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYTK

^$81.60

▲ +37.07% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $81.60, with a high forecast of $108.00 and a low forecast of $50.00. The average price target represents a 37.07% upside from the last price of $59.53.

Current Consensus is Moderate Buy

The current consensus among 15 contributing investment analysts is to moderate buy stock in Cytokinetics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/24/2022

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/22/2023

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/23/2023

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/21/2023

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/19/2023

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/17/2024

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/17/2024

0 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/17/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/14/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$94.00	Low
5/9/2024	JMP Securities	Lower Target	Market Outperform ➝ Market Outperform	$110.00 ➝ $106.00	Low
5/9/2024	Oppenheimer	Lower Target	Outperform ➝ Outperform	$107.00 ➝ $106.00	Low
5/9/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$108.00	Low
5/8/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$94.00	Low
4/9/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$108.00	Low
4/8/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$86.00	Low
3/6/2024	Mizuho	Lower Target	Buy ➝ Buy	$103.00 ➝ $99.00	Low
3/4/2024	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$107.00	Low
2/28/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$94.00	Low
2/28/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$108.00	Low
1/24/2024	UBS Group	Downgrade	Buy ➝ Neutral	$61.00 ➝ $92.00	Low
1/22/2024	Mizuho	Boost Target	Buy ➝ Buy	$80.00 ➝ $103.00	Low
1/5/2024	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$60.00 ➝ $90.00	Low
12/28/2023	Truist Financial	Boost Target	Buy ➝ Buy	$60.00 ➝ $86.00	Low
12/28/2023	Raymond James	Boost Target	Outperform ➝ Outperform	$63.00 ➝ $92.00	Low
12/27/2023	Needham & Company LLC	Boost Target	Buy ➝ Buy	$60.00 ➝ $108.00	Low
12/27/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$58.00 ➝ $94.00	Low
11/9/2023	The Goldman Sachs Group	Initiated Coverage	Buy	$50.00	Low
11/7/2023	B. Riley	Initiated Coverage	Buy	$66.00	Low
11/1/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$58.00	Low
10/20/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$60.00	Low
10/20/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$49.00 ➝ $58.00	Low
10/9/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$71.00	Low
10/9/2023	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$59.00 ➝ $65.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$59.00	Low
8/15/2023	Leerink Partnrs	Reiterated Rating	Outperform		Low
8/15/2023	SVB Leerink	Initiated Coverage	Outperform	$58.00	Low
8/15/2023	SVB Securities	Initiated Coverage	Outperform	$58.00	Low
8/4/2023	Morgan Stanley	Reiterated Rating	Overweight ➝ Overweight	$60.00	Low
8/4/2023	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
8/4/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$49.00	Low
6/22/2023	JPMorgan Chase & Co.	Boost Target		$52.00 ➝ $54.00	Low
5/5/2023	UBS Group	Boost Target		$61.00 ➝ $62.00	Low
4/3/2023	UBS Group	Lower Target	Buy	$67.00 ➝ $61.00	Low
4/3/2023	Cantor Fitzgerald	Lower Target	Overweight	$61.00 ➝ $59.00	Low
4/2/2023	Bank of America	Lower Target		$50.00 ➝ $42.00	Low
3/31/2023	HC Wainwright	Lower Target	Buy	$56.00 ➝ $49.00	Low
3/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$61.00	N/A
3/6/2023	Mizuho	Initiated Coverage	Buy	$80.00	Low
3/2/2023	The Goldman Sachs Group	Lower Target	Buy	$56.00 ➝ $48.00	Low
3/2/2023	JMP Securities	Reiterated Rating	Buy	$71.00	Low
3/1/2023	Needham & Company LLC	Reiterated Rating	Buy	$58.00	Low
3/1/2023	Oppenheimer	Lower Target	Outperform	$55.00 ➝ $54.00	Low
2/17/2023	Bank of America	Initiated Coverage	Neutral	$49.00	Low
1/17/2023	The Goldman Sachs Group	Boost Target	Buy	$47.00 ➝ $56.00	Low
12/23/2022	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $58.00	Low
12/20/2022	Truist Financial	Initiated Coverage	Buy	$60.00	Low
12/16/2022	Mizuho	Initiated Coverage	Buy	$80.00	Low
12/15/2022	UBS Group	Lower Target	Neutral	$80.00 ➝ $66.00	Low
12/15/2022	The Goldman Sachs Group	Lower Target	Buy	$55.00 ➝ $47.00	Low
12/15/2022	HC Wainwright	Boost Target	Buy	$29.00 ➝ $56.00	Low
12/14/2022	Oppenheimer	Lower Target		$55.00	Low
12/14/2022	HC Wainwright	Lower Target		$75.00 ➝ $29.00	Low
12/14/2022	JMP Securities	Lower Target	Market Outperform	$82.00 ➝ $71.00	Low
12/9/2022	JPMorgan Chase & Co.	Lower Target		$64.00 ➝ $55.00	Low
12/8/2022	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
10/11/2022	UBS Group	Initiated Coverage	Buy	$80.00	Low
10/3/2022	JMP Securities	Boost Target	Market Outperform	$53.00 ➝ $82.00	Low
9/2/2022	Mizuho	Initiated Coverage	Buy	$80.00	Low
8/15/2022	Cantor Fitzgerald	Boost Target		$56.00 ➝ $69.00	Low
8/12/2022	Morgan Stanley	Boost Target		$11.00 ➝ $15.00	Low
8/5/2022	Raymond James	Boost Target		$54.00 ➝ $63.00	Low
7/15/2022	Morgan Stanley	Boost Target	Overweight	$46.00 ➝ $60.00	Low
6/9/2022	Piper Sandler	Boost Target	Overweight	$50.00 ➝ $72.00	Medium
5/24/2022	HC Wainwright	Reiterated Rating	Buy	$75.00	Medium
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$71.00 ➝ $57.00	Low
5/16/2022	Mizuho	Boost Target	Buy ➝ Buy	$54.00 ➝ $80.00	Medium
5/5/2022	Needham & Company LLC	Boost Target		$52.00 ➝ $60.00	High
4/29/2022	HC Wainwright	Boost Target		$69.00 ➝ $75.00	High
2/17/2022	Cantor Fitzgerald	Lower Target		$57.00 ➝ $53.00	High
1/28/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$74.00	High
12/21/2021	Oppenheimer	Initiated Coverage	Outperform	$55.00	High
12/21/2021	HC Wainwright	Boost Target	Buy	$62.00 ➝ $69.00	High
12/10/2021	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$58.00	Medium
12/1/2021	Mizuho	Boost Target	Buy	$45.00 ➝ $54.00	High
11/4/2021	HC Wainwright	Boost Target	Positive ➝ Buy	$58.00 ➝ $62.00	High
11/4/2021	JMP Securities	Reiterated Rating	Buy		High
10/12/2021	Cantor Fitzgerald	Boost Target	Overweight	$48.00 ➝ $57.00	Low
10/8/2021	HC Wainwright	Reiterated Rating	Buy	$58.00	Medium
10/8/2021	Morgan Stanley	Boost Target	Overweight	$38.00 ➝ $45.00	Medium
10/6/2021	Jefferies Financial Group	Initiated Coverage	Buy	$75.00	High
9/7/2021	Barclays	Boost Target	Overweight	$40.00 ➝ $45.00	High
8/9/2021	Piper Sandler	Lower Target	Overweight	$42.00 ➝ $40.00	Low
8/6/2021	HC Wainwright	Boost Target	Buy	$53.00 ➝ $58.00	High
7/20/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$35.00 ➝ $48.00	High
7/20/2021	Barclays	Boost Target	Overweight	$28.00 ➝ $40.00	High
7/19/2021	JMP Securities	Boost Target	Outperform ➝ Outperform	$26.00 ➝ $44.00	High
7/19/2021	Raymond James	Boost Target	Outperform	$37.00 ➝ $54.00	High
7/19/2021	Piper Sandler	Boost Target	Positive ➝ Overweight	$25.00 ➝ $42.00	High
7/19/2021	HC Wainwright	Boost Target	Buy	$41.00 ➝ $53.00	High
7/19/2021	Needham & Company LLC	Boost Target	Buy	$33.00 ➝ $48.00	High
7/1/2021	Mizuho	Initiated Coverage	Buy	$36.00	Low
5/11/2021	Mizuho	Boost Target	Buy	$26.00 ➝ $36.00	Medium
4/19/2021	Morgan Stanley	Boost Target	Overweight	$24.00 ➝ $35.00	Low
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$50.00	High
2/18/2021	Barclays	Initiated Coverage	Overweight	$28.00	High
1/20/2021	HC Wainwright	Boost Target	Buy	$22.00 ➝ $41.00	High
12/16/2020	Morgan Stanley	Boost Target	Overweight	$22.00 ➝ $24.00	Low
12/14/2020	Mizuho	Lower Target	Buy	$31.00 ➝ $26.00	High
11/24/2020	Raymond James	Reiterated Rating	Buy		High
11/23/2020	HC Wainwright	Lower Target	Buy	$43.00 ➝ $22.00	High
11/16/2020	Needham & Company LLC	Reiterated Rating	Buy	$33.00	Medium
11/16/2020	Morgan Stanley	Lower Target	Overweight	$24.00 ➝ $22.00	High
10/28/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$16.00	Low
10/12/2020	Morgan Stanley	Lower Target	Overweight	$35.00 ➝ $24.00	Low
10/8/2020	HC Wainwright	Lower Target	Positive ➝ Buy	$59.00 ➝ $43.00	High
10/6/2020	Cantor Fitzgerald	Boost Target	Overweight	$41.00 ➝ $48.00	Medium
7/23/2020	Piper Sandler	Boost Target	Overweight	$33.00 ➝ $36.00	Low
7/23/2020	HC Wainwright	Boost Target	Buy	$38.00 ➝ $59.00	Low
7/15/2020	Cantor Fitzgerald	Boost Target	Overweight	$29.00 ➝ $41.00	High
7/15/2020	JMP Securities	Boost Target	Outperform	$23.00 ➝ $29.00	High
7/14/2020	Needham & Company LLC	Boost Target	Buy	$34.00 ➝ $45.00	High
7/14/2020	Piper Sandler	Boost Target		$28.00 ➝ $33.00	High
7/14/2020	HC Wainwright	Boost Target	Buy	$35.00 ➝ $38.00	High
7/10/2020	Raymond James	Initiated Coverage	Strong-Buy	$39.00	High
7/7/2020	Morgan Stanley	Boost Target	Overweight	$29.00 ➝ $35.00	High
5/23/2020	Mizuho	Initiated Coverage	Buy	$31.00	Low
5/12/2020	Morgan Stanley	Boost Target	Overweight	$25.00 ➝ $29.00	Low
5/11/2020	HC Wainwright	Boost Target	Positive ➝ Buy	$30.00 ➝ $35.00	High
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Low
5/4/2020	Mizuho	Initiated Coverage	Buy	$31.00	High
4/27/2020	Morgan Stanley	Reiterated Rating	Buy	$25.00	Low
4/24/2020	HC Wainwright	Reiterated Rating	Buy		Medium
4/19/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		Low
4/17/2020	Cantor Fitzgerald	Boost Target	Overweight	$12.00 ➝ $23.00	High
4/14/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	Medium
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Low
4/9/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$14.00 ➝ $25.00	High
3/31/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	High
3/4/2020	Needham & Company LLC	Reiterated Rating	Buy	$24.00	Medium
2/26/2020	HC Wainwright	Reiterated Rating	Buy	$30.00	Low
2/7/2020	HC Wainwright	Reiterated Rating	Buy		High
11/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$24.00	High
10/4/2019	Needham & Company LLC	Reiterated Rating	Buy	$16.00	Low
10/4/2019	HC Wainwright	Reiterated Rating	Buy	$26.00	Medium
9/16/2019	Piper Sandler Companies	Reiterated Rating	Overweight	$14.00 ➝ $20.00	High
9/13/2019	JMP Securities	Set Target	Buy	$23.00	Medium
9/6/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$14.00 ➝ $20.00	Medium
8/9/2019	Needham & Company LLC	Set Target	Buy	$16.00	Medium
8/9/2019	Morgan Stanley	Set Target	Hold	$16.00	Medium
7/15/2019	Morgan Stanley	Set Target	Hold	$11.00	High
7/15/2019	Piper Sandler Companies	Set Target	Buy	$14.00	High

(Data available from 5/18/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
9 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

10/21/2023

2 very positive mentions
14 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/20/2023

5 very positive mentions
9 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/20/2023

19 very positive mentions
46 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

1/19/2024

14 very positive mentions
28 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/18/2024

20 very positive mentions
42 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

3/19/2024

14 very positive mentions
16 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

4/18/2024

21 very positive mentions
36 positive mentions
3 negative mentions
2 very negative mentions

Mentions as of

5/18/2024

Current Sentiment

Recent Stories by Sentiment

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $59.53

$58.64

$60.47

50 Day Range

MA: $66.71

$57.89

$75.05

52 Week Range

Now: $59.53

$25.98

$110.25

Volume

1,056,731 shs

Average Volume

2,676,572 shs

Market Capitalization

$6.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?: The following equities research analysts have issued research reports on Cytokinetics in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for CYTK.
What is the current price target for Cytokinetics?: 15 Wall Street analysts have set twelve-month price targets for Cytokinetics in the last year. Their average twelve-month price target is $81.60, suggesting a possible upside of 37.1%. Needham & Company LLC has the highest price target set, predicting CYTK will reach $108.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $50.00 for Cytokinetics in the next year.
View the latest price targets for CYTK.
What is the current consensus analyst rating for Cytokinetics?: Cytokinetics currently has 2 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CYTK.
What other companies compete with Cytokinetics?: Other companies that are similar to Cytokinetics include Blueprint Medicines, Ionis Pharmaceuticals, Organon & Co., BridgeBio Pharma and Intra-Cellular Therapies. Learn More about companies similar to Cytokinetics.
How do I contact Cytokinetics' investor relations team?: Cytokinetics' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 624-3000 and its investor relations email address is [email protected]. The official website for Cytokinetics is www.cytokinetics.com. Learn More about contacing Cytokinetics investor relations.

Cytokinetics - CYTK Stock Price Target and Predictions

Analyst Price Target for CYTK

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.56 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytokinetics?

What is the current price target for Cytokinetics?

What is the current consensus analyst rating for Cytokinetics?

What other companies compete with Cytokinetics?

How do I contact Cytokinetics' investor relations team?